CSIMarket
 


Zyla Life Sciences  (EGLT)
Other Ticker:  
 

Cumulative Zyla Life Sciences's Working Capital Ratio for Trailing Twelve Months Period

EGLT's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

EGLT Working Capital Ratio for Trailing Twelve Months Period

(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
Y / Y Current Liabilities Growth 23.44 % 128.6 % -53.34 % 4.21 % 82.13 %
Y / Y Current Assets Growth -21.67 % -5.3 % -14.64 % -40.74 % -18.84 %
Working Capital Ratio for Trailing Twelve Months Period 0.71 0.81 0.95 0.74 0.85
Total Ranking # 4336 # 4211 # 3750 # 4161 # 4205
Seq. Current Liabilities Growth 22.79 % -0.43 % 17.92 % -14.38 % 127.4 %
Seq. Current Assets Growth 16.62 % -8.27 % 12.12 % -34.69 % 40.99 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2020
On the trailing twelve months basis Due to growth in Current Liabilities in the I. Quarter to $93 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 0.71 below Zyla Life Sciences average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 452 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Zyla Life Sciences. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about EGLT
Working Capital Ratio EGLT in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 453
Sector # 867
S&P 500 # 4303


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
5.78 2.97 0.71
(Mar 31 2015)   (Mar 31 2020)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Mar 31 2020, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Aeterna Zentaris Inc   1.93 
Aveo Pharmaceuticals Inc   1.92 
Wave Life Sciences Ltd   1.91 
Ibio inc   1.91 
Pulmatrix Inc   1.88 
Aptevo Therapeutics Inc   1.88 
Orgenesis Inc   1.86 
Avid Bioservices Inc   1.86 
Dr Reddy s Laboratories Limited  1.85 
Akebia Therapeutics Inc   1.82 
Nature s Sunshine Products inc   1.81 
Sellas Life Sciences Group Inc   1.79 
Bellicum Pharmaceuticals Inc   1.78 
Sophiris Bio Inc.  1.76 
Leap Therapeutics inc   1.76 
Corbus Pharmaceuticals Holdings Inc   1.73 
Trillium Therapeutics Inc   1.72 
Agex Therapeutics Inc   1.72 
Amag Pharmaceuticals inc   1.71 
Neptune Wellness Solutions Inc   1.71 
Panbela Therapeutics Inc   1.70 
Nanoviricides inc   1.70 
Omeros Corp  1.67 
Tg Therapeutics Inc   1.66 
Sanofi  1.64 
Endo International Plc  1.62 
Akari Therapeutics Plc  1.62 
Soligenix inc   1.61 
Novabay Pharmaceuticals Inc   1.60 
Lifevantage Corp  1.58 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com